Literature DB >> 10870053

Dermatofibrosarcoma protuberans: A clinicopathologic analysis of patients treated and followed at a single institution.

W B Bowne1, C R Antonescu, D H Leung, S C Katz, W G Hawkins, J M Woodruff, M F Brennan, J J Lewis.   

Abstract

BACKGROUND: Despite optimal surgical therapy for patients with dermatofibrosarcoma protuberans (DFSP), some patients still continue to develop local recurrence. The authors' objective was to identify and analyze clinicopathologic factors for disease free survival in a large group of patients who were followed prospectively at a single institution.
METHODS: Prospectively collected data and pathology slides were available for review from 159 patients with primary or recurrent DFSP who underwent treatment between July 1950 and July 1998. The study group was comprised of patients with either the "classic" form of DFSP or the fibrosarcomatous "high grade" variant of DFSP (FS-DFSP). Patient, tumor, pathologic, and treatment factors were analyzed using the log rank test for univariate influence and Cox regression analysis for multivariate influence. Local recurrence free survival was determined by the Kaplan-Meier actuarial method.
RESULTS: Of the 159 patients who comprised the current study group, 134 (84%) had the classic form of DFSP. The FS-DFSP variant was found in the remaining 25 patients (16%). The overall 5-year local recurrence free survival rate was 75%, with a median follow-up of 4. 75 years. The 5-year recurrence free survival rate for each group was 81% and 28%, respectively. On univariate analysis, age > 50 years, very close (< 1 mm) to positive microscopic margins, FS-DFSP variant, high mitotic rate, and increased cellularity were unfavorable prognostic factors. Multivariate analysis determined very close (< 1 mm) to positive microscopic margins and FS-DFSP variant to be independent adverse prognostic factors. For the 34 patients who developed a recurrence after surgical resection (21%), the median time to local recurrence was 32 months. Of the patients in this group, two died from metastatic disease.
CONCLUSIONS: The prognosis after surgical resection with negative and sometimes positive microscopic margins for patients with DFSP is very good. However, increased age, high mitotic index, and increased cellularity are predictors of poor clinical outcome. The FS-DFSP variant represents a much more aggressive tumor with metastatic potential. Patients who are treated with curative intent for FS-DFSP should undergo aggressive attempts at complete surgical resection. Patients with recurrent classic DFSP without evidence of adverse prognostic features may benefit from conservative management, especially in the setting of potentially unresectable disease. Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Year:  2000        PMID: 10870053

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  69 in total

Review 1.  Targeted therapy for dermatofibrosarcoma protuberans.

Authors:  Thomas A Abrams; Scott M Schuetze
Journal:  Curr Oncol Rep       Date:  2006-07       Impact factor: 5.075

2.  PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants.

Authors:  Khadijeh Jahanseir; Deyin Xing; Patricia T Greipp; William R Sukov; Gary L Keeney; Brooke E Howitt; J Kenneth Schoolmeester
Journal:  Int J Gynecol Pathol       Date:  2018-11       Impact factor: 2.762

3.  CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans.

Authors:  Grant Eilers; Jeffrey T Czaplinski; Mark Mayeda; Nacef Bahri; Derrick Tao; Meijun Zhu; Jason L Hornick; Neal I Lindeman; Ewa Sicinska; Andrew J Wagner; Jonathan A Fletcher; Adrian Mariño-Enriquez
Journal:  Mol Cancer Ther       Date:  2015-04-07       Impact factor: 6.261

4.  Soft tissue tumors of the anorectum: rare, complex and misunderstood.

Authors:  Mohammed O Nassif; Nora H Trabulsi; Kelli M Bullard Dunn; Ayoub Nahal; Ari-Nareg Meguerditchian
Journal:  J Gastrointest Oncol       Date:  2013-03

5.  Dermatofibrosarcoma Protuberans of the Breast-a Rare Entity.

Authors:  Suvendu Maji; M J Paul; Supriya Sen
Journal:  Indian J Surg Oncol       Date:  2017-08-10

6.  Magnetic resonance imaging and mammographic appearance of dermatofibrosarcoma protuberans in a male breast: a case report and literature review.

Authors:  Xin Chen; Yung Hsin Chen; Yi-Li Zhang; You-Min Guo; Zhi-Lan Bai; Xian Zhao
Journal:  J Med Case Rep       Date:  2009-06-16

7.  Intracranial recurrence and distant metastasis of scalp dermatofibrosarcoma protuberans.

Authors:  Jurica Marakovic; Milorad Vilendecic; Tonko Marinovic; Smiljka Lambasa; Gordan Grahovac
Journal:  J Neurooncol       Date:  2008-03-15       Impact factor: 4.130

8.  Abdominoplasty and thoraco-epigastric flaps for large anterior trunk defects after dermatofibrosarcoma protuberans wide resection: Two illustrative cases.

Authors:  Diogo Casal; Nuno Fradinho; Luísa Ramos; João Ferreira; Alice Varanda; Cláudia Diogo; José Baltazar; Mário Fernandes; Carlos Correia; Maria-Angélica Almeida
Journal:  Int J Surg Case Rep       Date:  2012-11-10

9.  Sunitinib for patients with locally advanced or distantly metastatic dermatofibrosarcoma protuberans but resistant to imatinib.

Authors:  Yan Fu; Huanrong Kang; Hui Zhao; Jia Hu; Huanhuan Zhang; Xiaosong Li; Nan Du; Yitao Huang
Journal:  Int J Clin Exp Med       Date:  2015-05-15

10.  Imatinib in the treatment of dermatofibrosarcoma protuberans.

Authors:  Stefanos V Labropoulos; Evangelia D Razis
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.